Skip to main content

Advertisement

Table 4 Clinical parameters, antimicrobial regimens and treatment outcome of patients with bloodstream infection (BSI) due to PER-1-positive P. aeruginosa (PER-1-Pa) isolates

From: Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase

Isolate Age (yr) Sex a McCabe & Jackson b Charlson weighted index Primary source(s)
of infection c
Severity of septicemia Empirical treatment Treatment administered after ID
and AST d results
Treatment outcome e
        Agent
(daily dose)
Adequate Agent
(daily dose)
Timing from
BSI onset
Duration
(days)
 
338/98 58 M NF 1 Unknown Severe sepsis SXT (10 ml × 3) No AMK (0.5 g × 2)
FEP (2 g × 3)
Day 4
Day 7
10
11
FA
LS034/99 60 M NF 0 LRTI Severe sepsis IPM (1.5 g × 3) No IPM (1.5 g × 3)
AMK (0.5 g × 2)
Day -21
Day -2
53
8
RE
140/99 69 M NF 1 Unknown Severe sepsis CTX (2 g × 3)
IPM (0.5 g × 3)
No Not changed Day -15
Day 0
20
5
FA
47/00 19 F NF 6 LRTI, IVC Sepsis MEM (1 g × 2)
AMK (1 g)
Yes MEM (1 g × 3)
AMK (1 g)
Day 1 6
18
FA
324/00 27 M NF 0 Unknown Sepsis CIP (0.4 g × 2) No Not changed Day 0 13 RE
A360/00 72 M RF 6 LRTI Sepsis None No MEM (0.5 g × 4)
AMK (0.75 g)
Day 3
Day 3
13 18 RE
527/00 60 M NF 3 Unknown Sepsis IPM (0.5 g × 4) No Not changed Day -9 13 CR
2126/01 67 F RF 6 UTI Sepsis CRO (2 g) No IPM (1 g × 3) Day 3 8 PR
A150/02 90 M UF 3 UTI Severe sepsis CIP (0.2 g × 2)
TZP (2 g × 2)
No IPM (0.5 g × 2) Day 1 11 RE
  1. Abbreviations for antimicrobial agents: SXT, trimethoprim-sulfametoxazole; PIP, piperacillin; TZP, piperacillin plus tazobactam; CRO, ceftriaxone; FEP, cefepime; IPM, imipenem; MEM, meropenem; CIP, ciprofloxacin; AMK, amikacin; GEN, gentamicin.
  2. a Sex: F, female; M, male.
  3. b McCabe & Jackson classification: NF, nonfatal; UF, ultimately-fatal; RF, rapidly-fatal.
  4. c Primary source(s) of infection: LRTI, lower respiratory tract infection; IVC, intravascular catheter colonization; UTI, urinary tract infection.
  5. d ID, identification; AST, antimicrobial susceptibility test.
  6. e Treatment outcome: CR, complete response; PR, partial response; FA, failure; RE, relapse.